请输入关键字
请输入关键字
百奥赛图将携RenLite平台和双抗ADC管线亮相WAC2022
2022.08.29


2022年第13届美国国际抗体偶联药物大会暨展览会(World ADC Conference,简称WAC)将于9月6-9日在美国San Diego举行,这是ADC领域最大的年度盛会之一,吸引了包括默克、艾伯维、礼来、第一三共、再生元、Seagen、Zymeworks等知名药企和创新生物技术企业的众多代表参加。百奥赛图新药研发及商务团队将与会交流。


from clipboard

公司研发高级总监Frank An博士将于9月6日上午10:30在会议中介绍公司RenLite平台,双抗、双抗ADC研发平台及相关管线的最新进展,报告题目为“Discovery of bispecific antibody drug conjugate (ADC) therapeutics with fully humanized RenLite common light chain transgenic mouse platform”。此外,商务团队将在会场设立展台(#45)并展示海报“YH013, a fully-human EGFR x MET bispecific ADC exhibits outstanding specificity and anti-tumor efficacy”。值得注意的是,此次是公司第一次对外展示YH013 双抗ADC数据。欢迎同仁与会交流,探索许可授权及共同开发机会。




W. Frank An, Ph.D., is the Senior Director of Antibody Therapeutics at Biocytogen. He obtained his Ph.D. in Cellular and Molecular Biology at Brandeis University, followed by postdoctoral fellowship in Immunology at Dana Farber Cancer Institute and Harvard Medical School. He has over twenty years’ experience working in drug discovery in both industry and academia settings.